Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
5 studies found for:    18650514 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Recruiting Efficacy and Safety of 'Immuncell-LC Group' and 'Non-treatment Group' in Nexavar Treated Patients for Advanced Hcc
Condition: Advanced Hepatocellular Carcinoma
Intervention: Drug: Immuncell-LC
2 Recruiting Efficacy and Safety of Concurrent TACE and Sorafenib in Patients With HCC and Extrahepatic Metastasis (COTSOM Study)
Conditions: Hepatocellular Carcinoma;   Metastasis
Interventions: Procedure: Conventional Transarterial Chemoembolization (TACE);   Drug: sorafenib
3 Completed
Has Results
A Phase III Study of Sorafenib in Patients With Advanced Hepatocellular Carcinoma
Condition: Carcinoma, Hepatocellular
Interventions: Drug: Sorafenib (Nexavar, BAY43-9006);   Drug: Placebo
4 Active, not recruiting TRC105 for Liver Cancer That Has Not Responded to Sorafenib
Conditions: Hepatocellular Carcinoma;   Hepatocellular Cancer;   Carcinoma, Hepatocellular
Intervention: Drug: TRC105
5 Recruiting Palliative Treatment of Hepatocellular Carcinoma in Patient With CHILD B Cirrhosis
Conditions: Hepatocellular Carcinoma;   CHILD B
Interventions: Drug: sorafenib;   Drug: Pravastatin;   Drug: Sorafenib + Pravastatin;   Other: patients receiving best supportive care

Indicates status has not been verified in more than two years